WHO ICTRP trial
Tofacitinib tablet bioequivalence
IRCT20130313012810N43 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20130313012810N43 |
|---|---|
| Public title | Tofacitinib tablet bioequivalence |
| Scientific title | Comparative bioequivalence study of the Tofacitinib 11-mg Extended-Release Tablets Manufactured by Noavaran Daroui Kimia Company |
| Primary sponsor | KIMIA Noavaran Daroui |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Bioequivalence study in healthy volunteers. |
| Interventions | Intervention 1: Intervention group 1: In this group, volunteers are given a single oral dose of Tofacitinib 11-mg tablets manufactured by Noavaran Daroui Kimia Pharmaceutical Company. In each period, 12 of 24 subjects will be given single… |
| Registration date | Dec 15, 2024 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: